DE69506197T2 - Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis - Google Patents
Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der PankreatitisInfo
- Publication number
- DE69506197T2 DE69506197T2 DE69506197T DE69506197T DE69506197T2 DE 69506197 T2 DE69506197 T2 DE 69506197T2 DE 69506197 T DE69506197 T DE 69506197T DE 69506197 T DE69506197 T DE 69506197T DE 69506197 T2 DE69506197 T2 DE 69506197T2
- Authority
- DE
- Germany
- Prior art keywords
- pancreatitis
- treatment
- compound
- phospholipase
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title description 6
- 229940115445 ascorbyl tocopheryl phosphate Drugs 0.000 title description 3
- IOZWJJBOYMUHEJ-HMQIKIGCSA-N [(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] hydrogen phosphate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP(O)(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O IOZWJJBOYMUHEJ-HMQIKIGCSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- -1 diester compound Chemical class 0.000 claims abstract description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 21
- 108010058864 Phospholipases A2 Proteins 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 239000004382 Amylase Substances 0.000 description 8
- 102000013142 Amylases Human genes 0.000 description 8
- 108010065511 Amylases Proteins 0.000 description 8
- 235000019418 amylase Nutrition 0.000 description 8
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229940126585 therapeutic drug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000772 camostat Drugs 0.000 description 3
- FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940043274 prophylactic drug Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000721 toxic potential Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18428294 | 1994-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69506197D1 DE69506197D1 (de) | 1999-01-07 |
| DE69506197T2 true DE69506197T2 (de) | 1999-04-15 |
Family
ID=16150598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69506197T Expired - Fee Related DE69506197T2 (de) | 1994-08-05 | 1995-08-01 | Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5650404A (enExample) |
| EP (1) | EP0699440B1 (enExample) |
| KR (1) | KR960006915A (enExample) |
| AT (1) | ATE173626T1 (enExample) |
| CA (1) | CA2152693A1 (enExample) |
| DE (1) | DE69506197T2 (enExample) |
| ES (1) | ES2124477T3 (enExample) |
| TW (1) | TW317500B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| AU2001236805B2 (en) * | 2000-02-11 | 2005-07-14 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| WO2002026238A1 (en) * | 2000-09-26 | 2002-04-04 | Vital Health Sciences Pty Ltd. | Phosphate derivative supplements |
| AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| JP4745608B2 (ja) | 2001-07-27 | 2011-08-10 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 電子伝達剤のリン酸誘導体を用いた皮膚治療 |
| US20030236301A1 (en) * | 2001-12-19 | 2003-12-25 | Bob Sanders | Liposomal delivery of vitamin E based compounds |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| ATE495730T1 (de) | 2004-03-03 | 2011-02-15 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
| EP2548581A3 (en) | 2005-06-17 | 2013-02-20 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| BRPI0621081A2 (pt) * | 2005-12-23 | 2011-11-29 | Vital Health Sciences Pty Ltd | método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos |
| ES2999020T3 (en) | 2010-02-05 | 2025-02-24 | Phosphagenics Ltd | Carrier comprising non-neutralised tocopheryl phosphate |
| SG184181A1 (en) | 2010-03-30 | 2012-10-30 | Phosphagenics Ltd | Transdermal delivery patch |
| RU2425669C1 (ru) * | 2010-04-13 | 2011-08-10 | Общество С Ограниченной Ответственностью "Гамаветфарм" | Средство для профилактики и лечения острого и хронического панкреатита |
| EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | AMINOCHINOLINE AS A KINASEHEMMER |
| CN108601732A (zh) | 2015-12-09 | 2018-09-28 | 磷肌酸有限公司 | 药物制剂 |
| KR102647670B1 (ko) | 2016-12-21 | 2024-03-15 | 아베초 바이오테크놀로지 리미티드 | 방법 |
| WO2021062347A1 (en) * | 2019-09-27 | 2021-04-01 | Duke University | Compositions and methods for the prevention and treatment of pancreatitis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219295A (ja) * | 1983-05-30 | 1984-12-10 | Senjiyu Seiyaku Kk | リン酸ジエステルまたはその塩およびそれらの製造法 |
| JPS62145019A (ja) * | 1985-12-19 | 1987-06-29 | Senjiyu Seiyaku Kk | 抗炎症剤 |
| JPS62205091A (ja) * | 1986-03-04 | 1987-09-09 | Senjiyu Seiyaku Kk | 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤 |
| JP2526059B2 (ja) * | 1987-04-28 | 1996-08-21 | 千寿製薬株式会社 | 抗潰瘍剤 |
| PH25859A (en) * | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
| JP2854631B2 (ja) * | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
-
1995
- 1995-06-27 CA CA002152693A patent/CA2152693A1/en not_active Abandoned
- 1995-06-28 TW TW084106619A patent/TW317500B/zh active
- 1995-07-18 US US08/503,722 patent/US5650404A/en not_active Expired - Fee Related
- 1995-08-01 ES ES95112104T patent/ES2124477T3/es not_active Expired - Lifetime
- 1995-08-01 DE DE69506197T patent/DE69506197T2/de not_active Expired - Fee Related
- 1995-08-01 EP EP95112104A patent/EP0699440B1/en not_active Expired - Lifetime
- 1995-08-01 AT AT95112104T patent/ATE173626T1/de not_active IP Right Cessation
- 1995-08-05 KR KR1019950024260A patent/KR960006915A/ko not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69506197D1 (de) | 1999-01-07 |
| EP0699440B1 (en) | 1998-11-25 |
| EP0699440A1 (en) | 1996-03-06 |
| US5650404A (en) | 1997-07-22 |
| ES2124477T3 (es) | 1999-02-01 |
| TW317500B (enExample) | 1997-10-11 |
| KR960006915A (ko) | 1996-03-22 |
| CA2152693A1 (en) | 1996-02-06 |
| ATE173626T1 (de) | 1998-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69506197T2 (de) | Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis | |
| DE69621756T2 (de) | Betahydroxybuttersäure oder Acetoessigsäure oder deren Salze oder Ester zur Verwendung zur Verbesserung der Gehirnfunktion | |
| DE3875285T2 (de) | Verwendung von salzen der n-acetylneuraminsaeure zur herstellung eines arzneimittels zum abschwellen der nasenschleimhaut. | |
| DE2614841C2 (enExample) | ||
| DE69010162T2 (de) | Zusammensetzung zur Behandlung von Entzündung. | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE69707372T2 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| DE3639378C2 (enExample) | ||
| DE69816493T2 (de) | Extrakt aus entzündetem Gewebe als Inhibitor der Stickstoffmonoxid-Produktion | |
| EP0236390B1 (de) | Mittel gegen multiple sklerose | |
| DE69501359T2 (de) | Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina | |
| DE60026491T2 (de) | Melagatran zur behandlung von entzündungen | |
| EP0024023B2 (de) | Antimykotische Mittel mit höherer Freisetzung der Wirkstoffe | |
| EP0267404B1 (de) | Dermale Behandlung von Wurmerkrankungen der Katze mit Praziquantel | |
| DE2514335A1 (de) | Oral zu verabreichendes arzneimittel mit antiplasmin-inhibitorwirkung | |
| DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
| DE3916417A1 (de) | Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid als aktive wirkstoffe | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE69125204T2 (de) | Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln | |
| CH621333A5 (enExample) | ||
| EP0028660B1 (de) | Xanthinoxydasehemmer und Verwendung von Benztriazinderivaten | |
| DE69600714T2 (de) | Antiallergische Zusammensetzung enthaltend eine Phosphorsäurediester-Verbindung | |
| EP0150248B1 (de) | Mittel zur Behandlung und Prophylaxe uratischer und gemischter uratischer Lithiasis | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |